Rybelsus sales disappoint while Ozempic surpasses expectations at Novo Nordisk

Compared to last year, both Rybelsus and Ozempic generated more revenue in Q2.

Photo: Novo Nordisk / PR

Novo Nordisk’s primary business area, dubbed Diabetes Care, fared worse than expected in the second quarter of 2022. The Ozempic drug once again generated higher-than-expected growth but Rybelsus disappointed compared to analyst estimates, the firm’s accounting report for the period showed Wednesday.

Overall diabetes revenue at Novo Nordisk totaled DKK 32.4bn (USD 4.4bn) in Q2 compared to DKK 26bn (USD 3.6bn) in the same period last year. This falls short of the analyst consensus estimate of DKK 32.6bn (USD 4.5bn) calculated by the pharmaceutical firm before the report was released.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs